Cullinan Therapeutics, Inc. (CGEM)
| Market Cap | 868.55M +79.1% |
| Revenue (ttm) | n/a |
| Net Income | -219.88M |
| EPS | -3.72 |
| Shares Out | 60.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 889,618 |
| Open | 14.30 |
| Previous Close | 14.25 |
| Day's Range | 14.13 - 14.66 |
| 52-Week Range | 5.68 - 16.74 |
| Beta | -0.11 |
| Analysts | Strong Buy |
| Price Target | 30.11 (+109.83%) |
| Earnings Date | May 7, 2026 |
About CGEM
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for CGEM stock is "Strong Buy." The 12-month stock price target is $30.11, which is an increase of 109.83% from the latest price.
News
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline ...
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, h...
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
CAMBRIDGE, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, h...
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
CAMBRIDGE, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, h...
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommend...
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31...
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01, 2...
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
PRINCETON, N.J. and TOKYO and CAMBRIDGE, Mass.
Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company accelerating potential high-impact therapies in autoimmune disea...
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Promising Phase 1 clinical data for CLN-049, a FLT3xCD3 bispecific T cell engager, demonstrating ~30% CRc rate in heavily pretreated, all-comer population of patients with relapsed/refractory AML to b...
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, regardless of FLT3 mutational status ~30% CRc rate obse...
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a cl...
Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations
Taiho Oncology Inc. and Cullinan Therapeutics Inc. (NASDAQ:CGEM) shared new data on Sunday from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib for advanced...
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
PRINCETON, N.J. and CAMBRIDGE, Mass., Oct. 12, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced new data from the central nervous system (CNS) involvement co...
Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, tod...
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer
Updated efficacy and safety data to be presented from the REZILIENT1 trial of zipalertinib from the cohort of patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor recepto...
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's disease
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
Advances Cullinan's leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology
PRINCETON, N.J. and CAMBRIDGE, Mass.
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today...
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
CAMBRIDGE, Mass. and TOKYO, Japan and PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today annou...
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025
Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren's Disease in the United States
CLN-978 is the first and only development-stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases Sjögren's disease represents the third indication under development for CLN...
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025
Cullinan and Taiho previously announced the Phase 2b portion of the study met the primary endpoint of overall response rate Cullinan and Taiho previously announced the Phase 2b portion of the study me...
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis
Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2 2025